Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $9.28 in the prior trading day, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $9.57, up 3.12%. In other words, the price has increased by $3.12 from its previous closing price. On the day, 2.75 million shares were traded. SPRY stock price reached its highest trading level at $9.7599 during the session, while it also had its lowest trading level at $9.25.
Ratios:
Our goal is to gain a better understanding of SPRY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.66.
On September 04, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $40.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’25 when Dorsey Brian sold 21,828 shares for $8.71 per share. The transaction valued at 190,050 led to the insider holds 10,789 shares of the business.
Chakma Justin sold 166,380 shares of SPRY for $1,476,147 on Nov 12 ’25. The Chief Business Officer now owns 0 shares after completing the transaction at $8.87 per share. On Nov 13 ’25, another insider, BRIAN T DORSEY, who serves as the Officer of the company, bought 21,828 shares for $8.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 945981120 and an Enterprise Value of 1773558400. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.63 while its Price-to-Book (P/B) ratio in mrq is 6.41. Its current Enterprise Value per Revenue stands at 12.422 whereas that against EBITDA is -19.749.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.81, which has changed by -0.34045488 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $6.66. The 50-Day Moving Average of the stock is 1.93%, while the 200-Day Moving Average is calculated to be -25.77%.
Shares Statistics:
The stock has traded on average 2.63M shares per day over the past 3-months and 2729520 shares per day over the last 10 days, according to various share statistics. A total of 98.84M shares are outstanding, with a floating share count of 59.72M. Insiders hold about 39.58% of the company’s shares, while institutions hold 64.44% stake in the company. Shares short for SPRY as of 1763078400 were 20140227 with a Short Ratio of 7.66, compared to 1760486400 on 18964276. Therefore, it implies a Short% of Shares Outstanding of 20140227 and a Short% of Float of 33.19.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of ARS Pharmaceuticals Inc (SPRY) in the stock market.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.49 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.75 and -$1.89 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.33, with 4.0 analysts recommending between -$0.92 and -$2.12.
Revenue Estimates
6 analysts predict $26.25M in revenue for. The current quarter. It ranges from a high estimate of $31.9M to a low estimate of $21.8M. As of. The current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $86.58MFor the next quarter, 6 analysts are estimating revenue of $25.32M. There is a high estimate of $29M for the next quarter, whereas the lowest estimate is $21M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $88.1M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $82.38M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $183.28M in the next fiscal year. The high estimate is $236M and the low estimate is $151M.
